CLINIPHAR LTD Raises Earnings Forecast — Net Profit 151.43/share
CLINIPHAR LTD (TSE:432A0) has revised its earnings forecast for the fiscal year ending March 2026, raising key profitability metrics while slightly lowering revenue expectations.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 3,767M | JPY 3,700M | -JPY 67M (-1.8%) |
| Operating Profit | JPY 95M | JPY 134M | +JPY 39M (+40.7%) |
| Ordinary Income | JPY 118M | JPY 146M | +JPY 28M (+23.0%) |
| Net Profit | JPY 118M | JPY 151M | +JPY 33M (+27.6%) |
| EPS | JPY 118.66/share | JPY 151.43/share | +JPY 32.87/share (+27.6%) |
The company cited improved operational efficiency and favorable foreign exchange conditions as key drivers behind the upward revision. Domestic operations benefited from optimized inventory management, enabling more agile product supply and higher profit margins. Meanwhile, overseas operations maintained stable supply chains through diversified logistics routes and flexible shipment scheduling. A weaker yen also contributed to the profit increase, as foreign currency gains were recorded in consolidated results.
The revision signals stronger-than-expected profitability, particularly from overseas operations and currency effects, which may bolster investor confidence in the company’s long-term growth prospects.